305 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
INCY Incyte Corporation $67.04 $14.25B N/A
Article Searches
Is Agenus Inc. (AGEN) a Buy? https://www.fool.com/investing/2018/05/12/is-agenus-inc-agen-a-buy.aspx?source=iedfolrf0000001 May 12, 2018 - This cancer-focused biotech will take plenty of shots on goal in the years ahead.
Incyte (INCY) Q1 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4168094-incyte-incy-q1-2018-results-earnings-call-transcript?source=feed_sector_healthcare May 01, 2018 - Incyte Corp. (NASDAQ:INCY)Q1 2018 Earnings CallMay 01, 2018 8:00 am ETExecutivesMichael Charles A. Booth - Incyte Corp.Hervé Hoppenot - Incyte Corp.Barry P. Flannelly - Incyte Corp.Steven H. Stein - I
Incyte (INCY) Incurs Loss in Q1, Revenues Miss Estimates http://www.zacks.com/stock/news/301776/incyte-incy-incurs-loss-in-q1-revenues-miss-estimates?cid=CS-ZC-FT-301776 May 01, 2018 - Incyte (INCY) reported disappointing results for the first quarter wherein the company reported a loss against expectation of earnings and sales too missed estimates.
Incyte (INCY) Reports A Loss in Q1 http://www.zacks.com/stock/news/301644/incyte-incy-reports-a-loss-in-q1?cid=CS-ZC-FT-301644 May 01, 2018 - Incyte reported a loss in the first quarter while sales also beat estimates.
Drug Stocks Q1 Earnings to Watch on May 1: PFE, MRK & More http://www.zacks.com/stock/news/301466/drug-stocks-q1-earnings-to-watch-on-may-1-pfe-mrk-more?cid=CS-ZC-FT-301466 Apr 30, 2018 - Four pharma/biotech companies are set to release earnings report on May 1. Let's take a look into how the companies are placed ahead of the upcoming results.
Should You Sell Incyte (INCY) Before Earnings? http://www.zacks.com/stock/news/301381/should-you-sell-incyte-incy-before-earnings?cid=CS-ZC-FT-301381 Apr 30, 2018 - Incyte (INCY) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to earnings beat.
Can Jafaki Help Incyte (INCY) Beat Earnings Estimates in Q1? http://www.zacks.com/stock/news/301187/can-jafaki-help-incyte-incy-beat-earnings-estimates-in-q1?cid=CS-ZC-FT-301187 Apr 27, 2018 - Incyte (INCY) is likely to beat on earnings when it reports first-quarter results on May 1 driven by strong Jakafi sales.
Biotech Stock Roundup: PRTA Down, AMGN Revises View, BIIB Misses on Sales http://www.zacks.com/stock/news/300782/biotech-stock-roundup-prta-down-amgn-revises-view-biib-misses-on-sales?cid=CS-ZC-FT-300782 Apr 25, 2018 - The biotech sector grabbed headlines last week as a couple of biotechs reported results while few others came out with pipeline updates.
Lessons to Learn From April's Biotech Blowups https://www.fool.com/investing/2018/04/25/lessons-to-learn-from-aprils-biotech-blowups.aspx?source=iedfolrf0000001 Apr 25, 2018 - Three biotechs reported devastating clinical trial failures this month. Here are the important takeaways.
Is Eli Lilly and Company a Buy? https://www.fool.com/investing/2018/04/25/is-eli-lilly-and-company-a-buy.aspx?source=iedfolrf0000001 Apr 25, 2018 - Lilly's first-quarter results looked good. Is it time to buy the big pharma stock?

Pages: 1...910111213141516171819...31

<<<Page 14>